Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Inclusion Criteria: * Participant is ≥ 18 years of age * The participant provides written informed consent for the trial * Participant is willing to comply with all study procedures for the duration of the study * Participant has a Karnofsky Performance Status ≥ 70% and/or ECOG 0-2 * Participant is a NSCLC subject prescribed immune checkpoint inhibitor systemic therapy according to on-label use with the target brain lesion(s) measuring ≥ 0.5 cm in longest diameter. Target mets may include: De novo mets for which surgery and radiation can be deferred, Mets with or without history of prior radiation, Mets with history of radiation after at least 8 weeks since last radiation treatment, and In the event a previously treated met has progressed according to institutional practice within 4 weeks post radiation treatment, the met may be study eligible, and/or if in the opinion of the Investigator, the subject may benefit from the study procedure. * Female subject is not planning pregnancy during the study duration and confirmed NOT PREGNANT each procedure day. * Screening/Baseline laboratory values Screening/Baseline should adhere to local standard of care lab values for ICI therapy Exclusion Criteria * Participant has evidence of acute intracranial hemorrhage * Participant at risk for spontaneous intracranial hemorrhage (e.g., history of metastatic melanoma or other tissue histology). * Participant has signs and symptoms of increased intracranial pressure or symptomatic mass effe…